Liquid biopsy of circulating tumor DNA and biosensor applications

Li, Xuanying; Ye, Mengsha; Zhang, Weiying; Tan, Duo; Jaffrézic‐Renault, Nicole; Yang, Xu; Guo, Zhenzhong

doi:10.1016/j.bios.2018.11.037

Cited by 71 publications

(58 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12,13 To date, consensus parameters have not been selected to detect the expression levels of different substances in body fluids. 12,13 To date, consensus parameters have not been selected to detect the expression levels of different substances in body fluids.…”

Section: B3galt5-as1 Detection In Serum Samplesmentioning

confidence: 99%

“…The emergence of noninvasive tumor diagnosis technology, that is, liquid biopsy, marks a great step forward in the process of overcoming tumor. 12,13 To date, consensus parameters have not been selected to detect the expression levels of different substances in body fluids. Several common reference genes 18S ribosomal RNA (18S), glyceraldehyde-3-phosphate dehydrogenase, U6 small nuclear RNA (U6), β-actin (ACTB), and tubulin (TUB) were selected for comparison by qRT-PCR in 10 mixed serum samples.…”

Section: B3galt5-as1 Detection In Serum Samplesmentioning

confidence: 99%

See 1 more Smart Citation

Abnormally expressed long noncoding RNA B3GALT5‐AS1 may serve as a biomarker for the diagnostic and prognostic of gastric cancer

Wei

Zong

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Early diagnosis of gastric cancer (GC) is an effective method to improve prognosis. Increasing number of long noncoding RNAs (lncRNAs) have been reported as biomarkers for several cancers. We aim to detect the level of lncRNA B3GALT5‐AS1 and its association with clinical parameters and to further explore its application value in GC. We measured serum B3GALT5‐AS1 expression in 107 patients with GC, 40 polyp patients, and 87 normal controls to explore the significance of serum B3GALT5‐AS1 in GC using the quantitative real‐time polymerase chain reaction method. The result demonstrated that B3GALT5‐AS1 level was markedly richer in GC patients than that in normal people (P < .001). B3GALT5‐AS1 may be served as a diagnostic marker for distinguishing GC patients from healthy people, and the proportion under the receiver operating characteristics curve is 0.816 (95% confidence interval, 0.758‐0.874; P = .03). Further exploration validated that high serum B3GALT5‐AS1 level was related to TNM stage (P = .024), and lymph node metastasis (P = .023). Our study suggested that serum B3GALT5‐AS1 may be employed as an ideal biomarker for early screening of GC.

show abstract

Section: B3galt5-as1 Detection In Serum Samplesmentioning

confidence: 99%

Section: B3galt5-as1 Detection In Serum Samplesmentioning

confidence: 99%

Abnormally expressed long noncoding RNA B3GALT5‐AS1 may serve as a biomarker for the diagnostic and prognostic of gastric cancer

Wei

Zong

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…Cancer is one of the leading causes of death worldwide. According to the World Health Organization (WHO) statistics, cancer accounts for 1/6 of the global death toll, and more than 40% of cancers can be overcome if they are diagnosed early [1].…”

Section: Introductionmentioning

confidence: 99%

“…Currently, ctDNA analysis is made mostly using sequencing-based technologies and PCR-based methods, as well as other advanced detection systems, including mass-spectrometry (MS), matrix-assisted laser desorption/ionization (MALDI), and surface-enhanced Raman scattering (SERS) [1,2,5,8,9]. However, these techniques are time-consuming and costly for their real accomplishment in a diagnostic set [2].…”

Section: Introductionmentioning

confidence: 99%

Opportunities, Challenges, and Prospects in Electrochemical Biosensing of Circulating Tumor DNA and Its Specific Features

Campuzano

Serafín

Gamella

et al. 2019

Sensors

View full text Add to dashboard Cite

Nowadays, analyzing circulating tumor DNA (ctDNA), a very small part of circulating free DNA (cfDNA) carried by blood, is considered to be an interesting alternative to conventional single-site tumor tissue biopsies, both to assess tumor burden and provide a more comprehensive snapshot of the time-related and spatial heterogeneity of cancer genetic/epigenetic scenery. The determination of ctDNA and/or mapping its characteristic features, including tumor-specific mutations, chromosomal aberrations, microsatellite alterations, and epigenetic changes, are minimally invasive, powerful and credible biomarkers for early diagnosis, follow-up, prediction of therapy response/resistance, relapse monitoring, and tracking the rise of new mutant subclones, leading to improved cancer outcomes This review provides an outline of advances published in the last five years in electrochemical biosensing of ctDNA and surrogate markers. It emphasizes those strategies that have been successfully applied to real clinical samples. It highlights the unique opportunities they offer to shift the focus of cancer patient management methods from actual decision making, based on clinic-pathological features, to biomarker-driven treatment strategies, based on genotypes and customized targeted therapies. Also highlighted are the unmet hurdles and future key points to guide these devices in the development of liquid biopsy cornerstone tools in routine clinical practice for the diagnosis, prognosis, and therapy response monitoring in cancer patients.

show abstract

“…Deoxyribonucleic acid/ribonucleic acid (DNA/RNA) are fundamental biomarkers for identification of specific disease [1][2][3] . For example, in a liquid biopsy, detecting and long-term tracking of circulating tumor DNA (ctDNA) in human blood are critical for early-stage cancer detection, treatment, and during remission 4 . Analysis of ctDNA is challenging due to its extremely low concentrations in human blood ( <1% in many cases) 5 .…”

Section: Introductionmentioning

confidence: 99%

Electrode_configuration_DNA_Sensitivity_Biomicrofluidics

Basuray¹

2019

Preprint

View full text Add to dashboard Cite

Electrical impedance spectroscopy (EIS) sensors through rapid and cost-effectiveoften suffer from poor sensitivity. EIS sensors modified with carbon-basedtransducers show a higher conductance, thereby increasing the sensitivity of the sensor towards biomolecules like DNA. However, the EIS spectra are compromised by the parasitic capacitance of the electric double layer (EDL). Here, a new shear-enhanced, flow-through nonporous, non-planar interdigitated microelectrode sensor has been fabricated that shifts the EDL capacitor to high frequencies. Enhanced convective transport in this sensor disrupts the diffusion dynamics of the EDL, shifting its EIS spectra to high frequency. Concomitantly, the DNA detection signal shifts to high frequency, making the sensor very sensitive, rapid with a high signal to noise ratio. The device consists of a microfluidic channel sandwiched between two sets of top and bottom interdigitated microelectrodes. One of the sets of microelectrodes is packed with carbon-based transducer material like carboxylated single-walled carbon nanotube (SWCNT). Multiple parametric studies of three different electrode configurations of the sensor along with different carbon-based transducer materials are undertaken to understand the fundamental physics and electrochemistry. Sensors packed with SWCNT show femtomolar detection sensitivity from all the different electrode configurations, for a short target-DNA. A 20-fold jump in the signal is noticed from the unique working electrode configuration in contrast to the other electrode configurations. This demonstrates the potential of the sensor for a significant increase in the sensitivity of the detection of DNA and other biomolecules.

show abstract

Liquid biopsy of circulating tumor DNA and biosensor applications

Cited by 71 publications

References 84 publications

Abnormally expressed long noncoding RNA B3GALT5‐AS1 may serve as a biomarker for the diagnostic and prognostic of gastric cancer

Abnormally expressed long noncoding RNA B3GALT5‐AS1 may serve as a biomarker for the diagnostic and prognostic of gastric cancer

Opportunities, Challenges, and Prospects in Electrochemical Biosensing of Circulating Tumor DNA and Its Specific Features

Electrode_configuration_DNA_Sensitivity_Biomicrofluidics

Contact Info

Product

Resources

About